Literature DB >> 4612530

Synthesis of complementary RNA sequences during productive adenovirus infection.

U Pettersson, L Philipson.   

Abstract

Liquid RNA.DNA hybridization with separated strands of adenovirus type 2 DNA revealed that late nuclear RNA can hybridize to about 85% of the 1-strand and 10-15% of the h-strand, whereas late cytoplasmic RNA hybridizes to 65-70% and 25% of the l- and h-strand, respectively. With separated strands from the six EcoRI fragments of adenovirus type 2 DNA as probes, it was shown that late nuclear RNA hydridizes to 85-90% of the l-strand from all six EcoRI fragments. Since late cytoplasmic RNA hybridizes to 40-50% of the h-strand from both fragments EcoRI-B and EcoRI-C, complementary viral RNA sequences are synthesized during adenovirus infection. Complementarity between nuclear and cytoplasmic RNA could also be demonstrated by showing that late cytoplasmic RNA which had been preincubated with late nuclear RNA hybridized to a smaller fraction of the h-strand of fragment EcoRI-C than without preincubation. Double-stranded RNA which contains sequences that correspond to at least 60% of the viral genome was isolated from infected cells. However, less than 2% of the newly synthesized late RNA became double-stranded after incubation under annealing conditions, which suggests that RNA derived from one of the strands is present at a low concentration. Accordingly, it was shown that nearly all viral cytoplasmic RNA which is synthesized late after infection is derived from the l-strand.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4612530      PMCID: PMC434004          DOI: 10.1073/pnas.71.12.4887

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Poly A and symmetrical transcription of SV40 DNA.

Authors:  Y Aloni
Journal:  Nat New Biol       Date:  1973-05-02

2.  Adenovirus messenger RNA in mammalian cells: failure of polyribosome association in the absence of nuclear cleavage.

Authors:  P M McGuire; C Swart; L D Hodge
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

3.  A procedure for the isolation of mammalian messenger ribonucleic acid.

Authors:  G Brawerman; J Mendecki; S Y Lee
Journal:  Biochemistry       Date:  1972-02-15       Impact factor: 3.162

4.  Processing of adenovirus specific nuclear RNA during virus replication.

Authors:  R Wall; L Philipson; J E Darnell
Journal:  Virology       Date:  1972-10       Impact factor: 3.616

5.  Identification of double-stranded virus-specific ribonucleic acid in KB cells infected with type 2 adenovirus.

Authors:  J J Lucas; H S Ginsberg
Journal:  Biochem Biophys Res Commun       Date:  1972-10-06       Impact factor: 3.575

6.  Addition of polyadenylate sequences to virus-specific RNA during adenovirus replication.

Authors:  L Philipson; R Wall; G Glickman; J E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1971-11       Impact factor: 11.205

7.  Symmetrical in vivo transcription of mitochondrial DNA in HeLa cells.

Authors:  Y Aloni; G Attardi
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

8.  Purification and properties of the replicative intermediate of the RNA bacteriophage R17.

Authors:  R M Franklin
Journal:  Proc Natl Acad Sci U S A       Date:  1966-06       Impact factor: 11.205

9.  Transcription and transport of virus-specific ribonucleic acids in African green monkey kidney cells abortively infected with type 2 adenovirus.

Authors:  J J Lucas; H S Ginsberg
Journal:  J Virol       Date:  1972-12       Impact factor: 5.103

10.  Extensive symmetrical transcription of Simian Virus 40 DNA in virus-yielding cells.

Authors:  Y Aloni
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

View more
  28 in total

1.  Viral RNA synthesis and levels of DNA-dependent RNA polymerases during replication of adenovirus 2.

Authors:  R Weinmann; J A Jaehning; H J Raskas; R G Roeder
Journal:  J Virol       Date:  1975-01       Impact factor: 5.103

2.  Termination sites for adenovirus type 2 DNA replication.

Authors:  A Tolun; U Pettersson
Journal:  J Virol       Date:  1975-10       Impact factor: 5.103

3.  The phosphorylation state of eucaryotic initiation factor 2 alters translational efficiency of specific mRNAs.

Authors:  R J Kaufman; M V Davies; V K Pathak; J W Hershey
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

4.  Adenovirus transcription. II. RNA sequences complementary to simian virus 40 and adenovirus 2DNA in AD2+ND1- and AD2+ND3-infected cells.

Authors:  S J Flint; Y Wewerka-Lutz; A S Levine; J Sambrook; P A Sharp
Journal:  J Virol       Date:  1975-09       Impact factor: 5.103

5.  Methylated simian virus 40-specific RNA from nuclei and cytoplasm of infected BSC-1 cells.

Authors:  S Lavi; A J Shatkin
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

6.  The adenovirus E1B 55-kilodalton and E4 open reading frame 6 proteins limit phosphorylation of eIF2alpha during the late phase of infection.

Authors:  Megan E Spurgeon; David A Ornelles
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

7.  RNA complementary to the genome of RNA tumor viruses in virions and virus-producing cells.

Authors:  E Stavnezer; G Ringold; H E Varmus; J M Bishop
Journal:  J Virol       Date:  1976-10       Impact factor: 5.103

8.  Adenovirus type 12 DNA sequences in primary hamster tumors.

Authors:  K C Lee; S Mak
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

9.  Transcription of the genome of adenovirus type 12. IV. Maps of stable late RNA from productively infected human cells.

Authors:  K H Scheidtmann; W Doerfler
Journal:  J Virol       Date:  1977-06       Impact factor: 5.103

10.  Adenovirus transcription. IV. Synthesis of viral-specific RNA in human cells infected with temperature-sensitive mutants of adenovirus 5.

Authors:  S M Berget; S J Flint; J F Williams; P A Sharp
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.